Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.25 - $8.54
Previous CloseN/A
Volume477.34K
Average Volume (3M)4.04M
Market Cap
$398.32M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Oct 30, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding93,561,750
10 Day Avg. Volume2,224,211
30 Day Avg. Volume4,041,312
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.30Price Target Upside313.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalysts have reiterated a 'Buy' recommendation, showing confidence in the stock.
Market PositionCOMP360 positions as a potential first-in-class treatment in a large, underserved depression market.
Regulatory ApprovalThe Phase 3 COMP005 trial delivered a regulatory win for COMP360, demonstrating statistically significant and clinically meaningful improvement on the MADRS scale.
Bears Say
Durability ConcernsDurability is a key component for commercial success, and there are concerns about the durability of CMPS' product.
Investor ExpectationsThe MADRS effect size of 3.6 points underwhelmed, as investors were citing around 4 points as the minimum to keep CMPS' stock flat for this trial.
Market ReactionThe market’s muted reaction to the COMP005 trial results—CMPS is down 20% since the data release—misrepresents the trial’s success, which provides a validated safety baseline and a credible efficacy signal.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.25 and its highest was $8.54 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $398.32M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 30, 2025 which is in 90 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Jul 31, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.023.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.41.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 93,561,750 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went up 0.535%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.30 (313.71% Upside)
$16.30 (313.71% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.22%
12-Months-Change
Fundamentals
Return on Equity
-60.67%
Trailing 12-Months
Asset Growth
3.28%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive developments such as successful trial results and a strong financial position. However, challenges in statistical power for the anorexia study and regulatory uncertainties were noted. Overall, the positive achievements in clinical trials and financial stability suggest an optimistic outlook.Read More>CMPS Stock 12 Month Forecast
Average Price Target
$16.30
▲(313.71%Upside)
Technical Analysis
Ownership Overview
21.25% Insiders
0.08% Mutual Funds
<0.01% Other Institutional Investors
75.79% Public Companies and Individual Investors